Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy
The success of gammadelta (gd) T cell-based immunotherapy, where the cytotoxic activity of circulating gd T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients´ gd T cells....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00643/full |
| _version_ | 1819178194755911680 |
|---|---|
| author | Hans-Heinrich eOberg Christian eKellner Matthias ePeipp Susanne eSebens Sabine eAdam-Klages Martin eGramatzki Dieter eKabelitz Daniela eWesch |
| author_facet | Hans-Heinrich eOberg Christian eKellner Matthias ePeipp Susanne eSebens Sabine eAdam-Klages Martin eGramatzki Dieter eKabelitz Daniela eWesch |
| author_sort | Hans-Heinrich eOberg |
| collection | DOAJ |
| description | The success of gammadelta (gd) T cell-based immunotherapy, where the cytotoxic activity of circulating gd T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients´ gd T cells. A possible influence of radio- or chemotherapy on gd T cells as well as their reported exhaustion after repetitive treatment with n-BP or their lack of response to various cancers can be easily determined by the monitoring assays described in this perspective article. Monitoring the absolute cell numbers of circulating gd T cell subpopulations in small volumes of whole blood from cancer patients and determining gd T cell-cytotoxicity using the Real-Time Cell Analyzer can give a more comprehensive assessment of a personalized tumor treatment. Possible future directions such as the combined usage of n-BP or phosphorylated antigens together with bispecific antibodies that selectively target gd T cells to tumor associated antigens, will be discussed. Such strategies induce expansion and enhance gd T cell-cytotoxicity and might possibly avoid their exhaustion and overcome the immunosuppressive tumor microenvironment. |
| first_indexed | 2024-12-22T21:38:41Z |
| format | Article |
| id | doaj.art-8f57567dcc854da79c19e32da11e3b0b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T21:38:41Z |
| publishDate | 2014-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8f57567dcc854da79c19e32da11e3b0b2022-12-21T18:11:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242014-12-01510.3389/fimmu.2014.00643122622Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapyHans-Heinrich eOberg0Christian eKellner1Matthias ePeipp2Susanne eSebens3Sabine eAdam-Klages4Martin eGramatzki5Dieter eKabelitz6Daniela eWesch7Institute of ImmunologyDivision of Stem Cell Transplantation and ImmunotherapyDivision of Stem Cell Transplantation and ImmunotherapyInstitute for Experimental MedicineInstitute of ImmunologyDivision of Stem Cell Transplantation and ImmunotherapyInstitute of ImmunologyInstitute of ImmunologyThe success of gammadelta (gd) T cell-based immunotherapy, where the cytotoxic activity of circulating gd T lymphocytes is activated by nitrogen-containing bisphosphonates (n-BP), or possibly by bispecific antibodies or the combination of both, requires a profound knowledge of patients´ gd T cells. A possible influence of radio- or chemotherapy on gd T cells as well as their reported exhaustion after repetitive treatment with n-BP or their lack of response to various cancers can be easily determined by the monitoring assays described in this perspective article. Monitoring the absolute cell numbers of circulating gd T cell subpopulations in small volumes of whole blood from cancer patients and determining gd T cell-cytotoxicity using the Real-Time Cell Analyzer can give a more comprehensive assessment of a personalized tumor treatment. Possible future directions such as the combined usage of n-BP or phosphorylated antigens together with bispecific antibodies that selectively target gd T cells to tumor associated antigens, will be discussed. Such strategies induce expansion and enhance gd T cell-cytotoxicity and might possibly avoid their exhaustion and overcome the immunosuppressive tumor microenvironment.http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00643/fullhumanMonitoringPancreatic Ductal AdenocarcinomaGamma Delta T cellsPhosphoantigenbispecific antibodies |
| spellingShingle | Hans-Heinrich eOberg Christian eKellner Matthias ePeipp Susanne eSebens Sabine eAdam-Klages Martin eGramatzki Dieter eKabelitz Daniela eWesch Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy Frontiers in Immunology human Monitoring Pancreatic Ductal Adenocarcinoma Gamma Delta T cells Phosphoantigen bispecific antibodies |
| title | Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy |
| title_full | Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy |
| title_fullStr | Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy |
| title_full_unstemmed | Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy |
| title_short | Monitoring circulating gammadelta T cells in cancer patients to optimize gammadelta T cell-based immunotherapy |
| title_sort | monitoring circulating gammadelta t cells in cancer patients to optimize gammadelta t cell based immunotherapy |
| topic | human Monitoring Pancreatic Ductal Adenocarcinoma Gamma Delta T cells Phosphoantigen bispecific antibodies |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2014.00643/full |
| work_keys_str_mv | AT hansheinricheoberg monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy AT christianekellner monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy AT matthiasepeipp monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy AT susanneesebens monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy AT sabineeadamklages monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy AT martinegramatzki monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy AT dieterekabelitz monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy AT danielaewesch monitoringcirculatinggammadeltatcellsincancerpatientstooptimizegammadeltatcellbasedimmunotherapy |